Format

Send to

Choose Destination
Gan To Kagaku Ryoho. 2019 Dec;46(12):1829-1834.

[Hurdles in Future Clinical Trials for Cancer Cachexia].

[Article in Japanese]

Author information

1
Division of Thoracic Oncology, Shizuoka Cancer Center.

Abstract

Cancer cachexia is a functional disorder which potentially co-exists in many types of malignancies. Its pathophysiology is macroscopically invisible by means of radiographic or pathologic tests. Recently, the international consensus on definition, diagnosis, and staging have been reported. However, the current diagnostic criteria is immature and unable to differentiate cancer cachexia from other similar disorders caused by aging, complications, disuse syndrome, or adverse events of cancer treatment. In addition, an early detection of pre-cachexia is still challenging. Despite vigorous efforts in development of treatment options, there is no standard treatment. There are discrepancies in recognition of clinically relevant outcomes among researchers, pharmaceutical companies, and regulatory authorities. True endpoint of cancer cachexia care may be the expansion of active life with better QOL. Although the classical endpoints of measuring body or lean body mass would be an important outcome, it may not always contribute as a true endpoint. Thus, an optimal measurable endpoint should be identified, and better combination of pharmacological and non-pharmacological treatments be established to improve functional prognosis in patients with cancer cachexia.

PMID:
31879397
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sunmedia PierOnline
Loading ...
Support Center